Therapeutic Advances in Chronic Disease最新文献

{"title":"Prevalence and determinants of metabolic syndrome among adults living with HIV on first-line antiretroviral treatment in southern Ethiopia: a cross-sectional study.","authors":"Agete Tadewos Hirigo, Daniel Yilma, Ayalew Astatkie, Zelalem Debebe","doi":"10.1177/20406223251346289","DOIUrl":"10.1177/20406223251346289","url":null,"abstract":"<p><strong>Background: </strong>Antiretroviral therapy (ART) has significantly reduced morbidity and mortality among people living with HIV (PLWH). However, data on the burden of metabolic syndrome (MetS) in sub-Saharan Africa remains limited, particularly following the implementation of universal test-and-treat strategies and the widespread use of integrase inhibitor-based combinations.</p><p><strong>Objective: </strong>This study aimed to determine the prevalence and associated factors of MetS among adults receiving first-line ART in the Hawassa City Administration, southern Ethiopia.</p><p><strong>Design: </strong>A cross-sectional study.</p><p><strong>Methods: </strong>The study was conducted from January 2023 to May 2024, adapting the World Health Organization (WHO) stepwise approach to collect data. All study-relevant data were collected from participants using a pretested structured questionnaire. MetS was defined according to the 2009 harmonized criteria. A binary logistic regression analysis was conducted to identify predictors of MetS, with adjusted odds ratio (aOR) and 95% confidence intervals (CIs).</p><p><strong>Results: </strong>A total of 450 adults participated in the study, of whom 262 (58.2%) were females. The mean (standard deviation) age of the participants was 41.1(±9.7) years. The prevalence of MetS was 36.4% (95% CI: 32.2-41.6), with low high-density lipoprotein (HDL) cholesterol as the most frequent component observed in 368 (81.8%) participants. Age >50 years (aOR: 2.9; 95% CI: 1.4-6.2), alcohol use (aOR: 2.7; 95% CI: 1.2-6.4), body mass index ⩾25 kg/m² (aOR: 3.7; 95% CI: 1.9-7.1), triglyceride/HDL-cholesterol ratio (aOR: 1.5; 95% CI: 1.3-1.7), family history of hypertension (aOR: 2.1; 95% CI: 1.1-3.8), and high waist-height ratio (aOR: 5.4; 95% CI: 1.8-15.9) were significantly associated with MetS. However, dolutegravir-based first-line regimens were not significantly associated with MetS (p=0.482 for DTG initiation, and p=0.34 for switching to DTG).</p><p><strong>Conclusion: </strong>The noticeable prevalence of MetS among PLWH highlights its potential to increase cardiovascular risks. Therefore, routine screening of PLWH for components of MetS is essential to reduce the health risks associated with metabolic disorders. As most of the identified risk factors are modifiable, implementing lifestyle interventions is also imperative.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"16 ","pages":"20406223251346289"},"PeriodicalIF":3.3,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12182631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144369197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Joint effects of sodium intake and circadian rhythm of urinary sodium excretion on prognosis of chronic kidney disease: a prospective study.","authors":"Yu He, Jiawen Li, Jialing Rao, Weiyan Lai, Qin Wei, Haiteng Li, Yuxuan Li, Hui Peng, Jun Zhang","doi":"10.1177/20406223251344474","DOIUrl":"10.1177/20406223251344474","url":null,"abstract":"<p><strong>Background: </strong>Sodium harmony is closely correlated with the progression of chronic kidney disease (CKD).</p><p><strong>Objectives: </strong>The current study aims to explore the significance of the circadian rhythm of urinary sodium excretion in CKD management and to help establish individualized salt restriction strategies.</p><p><strong>Design: </strong>This is a prospective study among inpatients with CKD.</p><p><strong>Methods: </strong>The study included 715 participants with CKD from the Third Affiliated Hospital of Sun Yat-Sen University. Multivariable Cox regression models and restricted cubic splines were employed to explore the independent and joint associations of 24-h urinary sodium and sodium rhythm with prognosis of CKD.</p><p><strong>Results: </strong>During a median follow-up of 6.92 years, 286 major renal events, 112 MACE, 160 deaths, and 321 composite events were documented. 24-h urinary sodium was not associated with any outcomes. However, there were dose-response associations of diurnal sodium/24-h urinary sodium with major renal events (<i>p</i> _overall < 0.001, <i>p</i> _nonlinearity = 0.016) and composite events (<i>p</i> _overall < 0.001, <i>p</i> _nonlinearity = 0.129). Compared with the combination of low 24-h sodium and normal sodium rhythm, the combination of high 24-h sodium and abnormal sodium rhythm had the highest risk of incident major renal events (hazard ratio, 1.62; 95% confidence interval, 1.04-2.51). A significant interaction was observed between sodium intake and sodium rhythm in associations with composite events (<i>p</i> for interaction = 0.015).</p><p><strong>Conclusion: </strong>The circadian rhythm of sodium excretion emerges as a novel and potentially more sensitive risk factor for the prognosis of CKD. Furthermore, the association between sodium intake and progression of CKD was notably pronounced among individuals with abnormal sodium rhythms. Efforts to implement individualized salt restriction strategies are warranted.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"16 ","pages":"20406223251344474"},"PeriodicalIF":3.3,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12181718/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144369196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic review: the use of tacrolimus in steroid-refractory ulcerative colitis.","authors":"Vinay Jangra, Dilsan Yilmaz, Delvene Soares, Fiona Taylor, Stefano Andreani, Alexander Hotouras","doi":"10.1177/20406223251333570","DOIUrl":"10.1177/20406223251333570","url":null,"abstract":"<p><strong>Background: </strong>Steroid-refractory ulcerative colitis (SR-UC) is a severe form of ulcerative colitis (UC) that persists despite high-dose corticosteroid therapy. Management is challenging and often requires biologics, immunosuppressants or colectomy. Tacrolimus, a calcineurin inhibitor with immunomodulatory effects, has emerged as a potential alternative, though its efficacy, safety and long-term outcomes remain uncertain.</p><p><strong>Objectives: </strong>This systematic review evaluates the efficacy and safety of tacrolimus in SR-UC, compares it with anti-tumour necrosis factor (TNF) agents, and examines its role in patients with steroid-refractory ulcerative proctitis (SR-UP).</p><p><strong>Design: </strong>A systematic review was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Studies were assessed using the Oxford Centre for Evidence-Based Medicine framework.</p><p><strong>Data sources and methods: </strong>A comprehensive search of PubMed and Medline (1998-2025) identified studies reporting clinical remission, response rates, adverse effects and colectomy rates. Subgroup analyses compared oral tacrolimus with anti-TNF therapy and evaluated topical tacrolimus in SR-UP.</p><p><strong>Results: </strong>Seventeen studies (658 patients) met the inclusion criteria. Tacrolimus demonstrated variable efficacy, with clinical remission rates of 9.4%-75.6% and response rates of 28.6%-89.6%. Adverse events, mainly neurotoxicity and nephrotoxicity, occurred in 16.7%-53.0% of cases, sometimes leading to treatment discontinuation. Colectomy rates ranged from 6.1% to 62%. No significant difference was observed between tacrolimus and anti-TNF agents in remission induction, though anti-TNFs had superior long-term outcomes. Topical tacrolimus showed promising efficacy in SR-UP (73.0%-75.0% remission) but was associated with high adverse event rates (45.0%-67.0%).</p><p><strong>Conclusion: </strong>Tacrolimus is a viable option for SR-UC, particularly in combination therapy, but its long-term efficacy remains uncertain. While it is comparable to anti-TNFs for short-term remission, high colectomy rates and adverse effects require careful monitoring. Topical tacrolimus shows promise for SR-UP but requires standardised dosing. Further large-scale trials are needed to optimise treatment strategies and evaluate long-term safety.</p><p><strong>Trial registration: </strong>The review has been registered with PROSPERO (CRD42023432827), the international prospective register of systematic reviews.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"16 ","pages":"20406223251333570"},"PeriodicalIF":3.3,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12166232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144302825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rosacea and treatment with retinoids: a systematic review and meta-analysis.","authors":"Alberto Sticchi, Flavio Fiorito, Shaniko Kaleci, Alessia Paganelli, Marco Manfredini, Caterina Longo","doi":"10.1177/20406223251339964","DOIUrl":"10.1177/20406223251339964","url":null,"abstract":"<p><strong>Background: </strong>Rosacea is a common inflammatory disease. Four clinical rosacea subtypes have been described, with the papulo-pustular being the most common. At present, the only FDA-approved treatment for papulo-pustular rosacea is low-dose doxycycline. Retinoids, in particular isotretinoin, have shown for decades positive outcomes in the treatment of rosacea, but due to the lack of robust evidence, they are still considered an off-label treatment for this condition.</p><p><strong>Objectives: </strong>Summarize the current evidence in the literature regarding the role of topical and systemic retinoids in the treatment of papulo-pustular rosacea.</p><p><strong>Design: </strong>Systematic review and meta-analysis.</p><p><strong>Data source and methods: </strong>A systematic MEDLINE, EMBASE, and Cochrane search of relevant publications on this topic was carried out. Randomized and non-randomized studies regarding topical and systemic retinoid treatment for rosacea were included. We excluded not relevant studies, case reports, reviews, and non-English language studies. We have used RoB2 and ROBINS-1 tool for assessing risk of bias in randomized and non-randomized trials, respectively.</p><p><strong>Results: </strong>Due to the heterogeneity in study design and outcomes reporting, the standardization of our results is limited, but the findings from this systematic review with meta-analysis indicate that retinoids, particularly isotretinoin, are a promising treatment option for papulopustular rosacea, with a favorable tolerability and safety profile. On the other hand, available data for topical retinoid therapy are less definitive and more contradictory, with only two randomized studies reporting opposite outcomes.</p><p><strong>Conclusion: </strong>Retinoids may be a valid treatment option for rosacea, but larger, randomized controlled trials are needed to establish standardized dosing regimens and long-term safety profiles.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"16 ","pages":"20406223251339964"},"PeriodicalIF":3.3,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12126652/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive factors for neuromodulator response in patients with nonacid gastroesophageal reflux-induced chronic cough: a retrospective data analysis.","authors":"Obama Oyana Marcelina Asangono, Yaxing Zhou, Jiguang Wu, Tongyangzi Zhang, Shengyuan Wang, Li Yu, Xianghuai Xu","doi":"10.1177/20406223251336036","DOIUrl":"10.1177/20406223251336036","url":null,"abstract":"<p><strong>Background: </strong>Nonacid gastroesophageal reflux-induced cough (GERC) remains understudied, with limited research on effective treatment options. Recently, neuromodulators such as gabapentin and baclofen have shown promise in managing nonacid GERC.</p><p><strong>Objectives: </strong>This study aimed to identify factors associated with response to neuromodulator therapy in nonacid GERC.</p><p><strong>Study design: </strong>A retrospective study.</p><p><strong>Methods: </strong>We analyzed medical records of patients diagnosed with nonacid GERC who received gabapentin or baclofen as an add-on therapy enrolled between December 2019 and January 2024. Retrospective analysis of general information, cough-related questionnaires, MII-pH parameters, and other assessments was conducted to establish a regression analysis model for identifying multiple factors associated with neuromodulator response.</p><p><strong>Results: </strong>In this retrospective cohort study, data from 184 patients were analyzed, with 106 (57.6%) classified as responders and 78 (42.4%) as nonresponders. Clinical factors significantly associated with neuromodulator efficacy included gender (OR = 4.324, <i>p</i> = 0.027), age (OR = 0.803, <i>p</i> = 0.002), and exposure to cough-aggravating factors (OR = 6.345, <i>p</i> < 0.001). Furthermore, multiple regression analysis further identified specific Hull Airway Reflux Questionnaire (HARQ) items-\"Cough with certain foods\" (OR = 2.523, <i>p</i> = 0.034), \"Cough with eating\" (OR = 4.445, <i>p</i> < 0.001), and \"Cough brought on by singing or speaking\" (OR = 5.003, <i>p</i> = 0.007)-as significant predictors. Additionally, Medication Adherence Questionnaire (MAQ) items such as \"Forgetfulness\" (OR = 0.257, <i>p</i> = 0.005) and \"Stopping medication when \"feeling better\" (OR = 0.787, <i>p</i> = 0.017) were also identified as significant predictors of treatment response.</p><p><strong>Conclusion: </strong>Neuromodulators can relieve nonacid GERC in patients unresponsive to standard anti-reflux therapy. Factors such as male gender, younger age, less exposure to cough irritants, and higher HARQ and lower MAQ scores can effectively predict the efficacy of neuromodulators.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"16 ","pages":"20406223251336036"},"PeriodicalIF":3.3,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12120281/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144182207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacotherapeutic perspectives on nutraceuticals in the treatment of MASLD and MASH.","authors":"Ali H Eid, Maha Khachab, Firas Kobeissy, Amirhossein Sahebkar","doi":"10.1177/20406223251339388","DOIUrl":"10.1177/20406223251339388","url":null,"abstract":"","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"16 ","pages":"20406223251339388"},"PeriodicalIF":3.3,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12103661/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterisation of non-cirrhotic MAFLD-related hepatocellular carcinoma: a retrospective cohort study.","authors":"Shadi Zerehpooshnesfchi, Fatema Safri, Ziyan Pan, Romario Nguyen, Lawrence Yuen, Vincent Lam, Christopher Nahm, Tony Pang, Golo Ahlenstiel, Jacob George, Mohammed Eslam, Liang Qiao","doi":"10.1177/20406223251339402","DOIUrl":"10.1177/20406223251339402","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is a major global health issue, in which the underlying liver disease aetiology has shifted towards non-viral causes, particularly metabolic (dysfunction)-associated fatty liver disease (MAFLD). While traditionally associated with cirrhosis, a subset of HCC cases arises in patients with MAFLD but without cirrhosis, whose characteristics remain poorly understood.</p><p><strong>Objectives: </strong>The study aims to explore the clinical, tumour and genetic characteristics of non-cirrhotic MAFLD-related HCC when compared to those that develop in the context of cirrhosis.</p><p><strong>Design: </strong>A multi-centre, retrospective study of 89 MAFLD-related HCC patients enrolled between 2009 and 2023 was performed.</p><p><strong>Methods: </strong>We conducted a study of well-defined MAFLD-related HCC patients to explore their MAFLD-related clinical and genetic associations. Statistical analysis was undertaken to compare the underlying cirrhosis and non-cirrhosis groups for HCC features, adjusting for relevant confounders.</p><p><strong>Results: </strong>Patients with HCC arising in cases of MAFLD without cirrhosis exhibited a lower body mass index, higher triglyceride levels and increased smoking prevalence compared to their counterparts with cirrhosis. Despite arising in the absence of cirrhosis, these patients had more aggressive tumour features, including larger tumour size, multifocality and portal vein thrombosis. Logistic regression confirmed non-cirrhosis status to be an independent predictor of larger tumour size and increased lesion number.</p><p><strong>Conclusion: </strong>Non-cirrhotic MAFLD-related HCC presents with distinct clinical and tumour characteristics, suggesting the existence of unique disease drivers that are yet to be discovered.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"16 ","pages":"20406223251339402"},"PeriodicalIF":3.3,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12084690/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144094912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Opportunities and challenges of lifestyle intervention-based digital therapeutics in LDL-C management: a scoping review.","authors":"Jia Tang, Tiantian Song, Ming Kuang, Hongying Liu","doi":"10.1177/20406223251334439","DOIUrl":"https://doi.org/10.1177/20406223251334439","url":null,"abstract":"<p><strong>Background: </strong>In recent decades, the prevalence of dyslipidemia, especially high low-density lipoprotein cholesterol (LDL-C), has risen sharply in China. Although lifestyle interventions are important, traditional face-to-face approaches have limitations. Digital Therapeutics (DTx) can provide an effective solution by delivering remote medical interventions to patients via software and hardware, thereby optimizing existing clinical treatment methods with enhanced convenience and accessibility.</p><p><strong>Objectives: </strong>This study aims to explore the current evidence on the effect of lifestyle intervention-based Digital Therapeutics (LI-DTx) on high LDL-C, and to analyze their advantages and disadvantages.</p><p><strong>Eligibility criteria: </strong>This scoping review examines clinical studies assessing the effects of DTx on LDL-C levels. Papers were included in the final analysis if there was evidence that DTx had effects on lowering LDL-C levels.</p><p><strong>Sources of evidence: </strong>Papers that were published between January 2014 and December 2023 were included in the PubMed database.</p><p><strong>Charting methods: </strong>Data extracted from the publications included country, year, study type, study population, sample size, study duration, intervention, and changes in LDL-C level.</p><p><strong>Results: </strong>A total of 23 target literature were identified. Twenty-one studies confirmed that LI-DTx could optimize the LDL-C level through remote lifestyle interventions such as diet, exercise, medication, and health education, of which 14 studies reported a significant reduction in LDL-C level (<i>p</i> < 0.05). In the future, the development and design of DTx will need to improve intelligence, personalization, applicability, real-time performance, and data security; integrate with traditional healthcare systems; facilitate multidisciplinary collaboration in dyslipidemia management; and enhance long-term patient engagement with DTx platforms.</p><p><strong>Conclusion: </strong>LI-DTx may offer a more effective and sustainable solution for LDL-C management, although several challenges remain. Further randomized controlled clinical trials are needed to provide scientific support for its efficacy and safety.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"16 ","pages":"20406223251334439"},"PeriodicalIF":3.3,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144080544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biological pathways and mechanisms linking COPD and cardiovascular disease.","authors":"Beatrice Ragnoli, Fausto Chiazza, Giovanni Tarsi, Mario Malerba","doi":"10.1177/20406223251314286","DOIUrl":"10.1177/20406223251314286","url":null,"abstract":"<p><p>Cardiovascular disease (CVD) still poses a significant risk for morbidity and mortality in patients with chronic obstructive pulmonary disease (COPD). For a long time, among functional parameters, only the forced expiratory volume in 1 s (FEV₁) has been considered as predictive of cardiovascular (CV) mortality especially in elderly patients in fact, there is evidence that reductions in lung function indices can increase the risk of ischaemic heart diseases and cerebrovascular diseases, independently from other risk factors. Now, there is considerable evidence suggesting that hypoxemia, systemic inflammation, oxidative stress and hyperinflation may lead to an early sub-clinical CV involvement in patients affected by COPD. Ageing in itself impacts specific aspects of the CV system, including reduced beta-adrenergic responsiveness, increased vagal tone and myocardial and vascular stiffness, endothelial dysfunction, diminished arterial baroreflex and compromised diastolic function. The complex involved interactions include ageing mechanisms as well as multiple known and unknown (e.g. genetic) risk factors. CVDs are leading causes of mortality in individuals with impaired lung function and the two entities commonly coexist with poor outcomes in patients experiencing both conditions. However, the precise mechanisms responsible for this association remain largely unknown. In this narrative review, we summarize current knowledge regarding the co-occurrence of COPD and CVD focusing on the shared biological pathways and biological mechanisms involved in these conditions.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"16 ","pages":"20406223251314286"},"PeriodicalIF":3.3,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954385/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143754208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship of sKlotho with hemoglobin level in patients undergoing maintenance hemodialysis: a case-control study.","authors":"Qi-Feng Liu, Zhuo-Yi Sun, Xiao-Fang Tang, Li-Xia Yu, Sha-Sha Li","doi":"10.1177/20406223251318481","DOIUrl":"10.1177/20406223251318481","url":null,"abstract":"<p><strong>Background: </strong>Klotho is a kidney-derived protein that is involved in various kidney diseases. The role of serum soluble Klotho (sKlotho) in the anemia of patients undergoing hemodialysis has not been well characterized.</p><p><strong>Objective: </strong>We aimed to characterize the relationship between sKlotho and hemoglobin (Hb) levels in this group of patients.</p><p><strong>Design: </strong>A single-center cross-sectional study of 208 patients undergoing maintenance hemodialysis (MHD) and 50 healthy controls was performed between June 1 and 31, 2023.</p><p><strong>Methods: </strong>Demographic information and biomedical parameters, such as age, body mass index, medication use, and their Hb, albumin, interleukin-6, and sKlotho concentrations, were obtained. Patients undergoing MHD were allocated to a group that achieved the Hb target (⩾110 g/L) and a group that did not (<110 g/L). Correlation analysis and multivariate logistic and linear regression analyses were performed to evaluate the relationship of sKlotho with Hb concentration.</p><p><strong>Results: </strong>Participants undergoing MHD had lower Hb and sKlotho concentrations than controls. Those who had not achieved the target Hb level were given fewer erythropoiesis-stimulating agents and had lower sKlotho and albumin concentrations, but higher interleukin-6 concentrations, than those who had achieved the Hb target. The sKlotho concentration positively correlated with the Hb concentration and was inversely associated with the incidence of a lack of achievement of the target Hb level. Multivariate logistic regression models revealed that there was a close association between sKlotho and a lack of achievement of the target Hb level after adjustment for potential confounders (odds ratio: 0.335, 95% confidence interval: 0.142-0.791, <i>p</i> = 0.013). This relationship was closer on multivariate linear regression analysis when sKlotho was included as a continuous variable.</p><p><strong>Conclusion: </strong>The circulating sKlotho concentration is very low, but deficiency of this protein is independently associated with a high risk of anemia in patients undergoing MHD. Therefore, the routine monitoring of sKlotho concentration might be useful in the management of renal anemia in such patients.</p>","PeriodicalId":22960,"journal":{"name":"Therapeutic Advances in Chronic Disease","volume":"16 ","pages":"20406223251318481"},"PeriodicalIF":3.3,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829302/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}